Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Lyons

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Paediatrics & Child Health|March 5, 2016
The Edmonton Obesity Staging System for Pediatrics: A proposed clinical staging system for paediatric obesityStasia Hadjiyannakis, Annick Buchholz, Jean-Pierre Chanoine, et al.
Molecular Cancer Therapeutics|June 21, 2012
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor modelsTomoko Smyth, Thomas Van Looy, Jayne E Curry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizerFang Fang, Joanne Munck, Jessica Tang, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Science (New York, N.Y.)|May 6, 2026
A 481-meter-high landslide-tsunami in a cruise ship-frequented Alaska fjordDan H Shugar, Katherine R Barnhart, Mira Berdahl, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Psicothema|July 12, 2017
[Therapeutic Residential Care for Children and Youth: A Consensus Statement of the International Work Group on Therapeutic Residential Care]James K Whittaker, Lisa Holmes, Jorge F Del Valle, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Science (New York, N.Y.)|May 13, 2022
Atmospheric waves and global seismoacoustic observations of the January 2022 Hunga eruption, TongaRobin S Matoza, David Fee, Jelle D Assink, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Paediatrics & Child Health|March 5, 2016
The Edmonton Obesity Staging System for Pediatrics: A proposed clinical staging system for paediatric obesityStasia Hadjiyannakis, Annick Buchholz, Jean-Pierre Chanoine, et al.
Molecular Cancer Therapeutics|June 21, 2012
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor modelsTomoko Smyth, Thomas Van Looy, Jayne E Curry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizerFang Fang, Joanne Munck, Jessica Tang, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Science (New York, N.Y.)|May 6, 2026
A 481-meter-high landslide-tsunami in a cruise ship-frequented Alaska fjordDan H Shugar, Katherine R Barnhart, Mira Berdahl, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Psicothema|July 12, 2017
[Therapeutic Residential Care for Children and Youth: A Consensus Statement of the International Work Group on Therapeutic Residential Care]James K Whittaker, Lisa Holmes, Jorge F Del Valle, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Science (New York, N.Y.)|May 13, 2022
Atmospheric waves and global seismoacoustic observations of the January 2022 Hunga eruption, TongaRobin S Matoza, David Fee, Jelle D Assink, et al.
Pageof 6